
Bayer HealthCare is releasing new evidence to suggest that the risk of taking its best-selling blood thinner Xarelto is outweighed …

German drug giant Bayer is sealing a $155 million deal with Isis Pharmaceuticals to gain access to its anti-clotting treatment …

Bayer’s pharmaceutical revenues have continued their upward trajectory in the first quarter of 2015 thanks to new products, although this …

Bristol-Myers Squibb and Pfizer’s Eliquis for preventing blood clots has been shown the green light to treat venous thromboembolism (VTE), …

Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …

Boehringer Ingelheim says that its investigational drug can safely reverse the blood-thinning effect of its anti-clotting drug Pradaxa (dabigatran). The …

Pfizer and Bristol-Myers Squibb have been handed a much-needed lift after its new blood thinner Eliquis gained a licence extension …

Pfizer and Bristol-Myers Squibb have submitted their oral direct Factor Xa inhibitor Eliquis to the FDA to prevent deep vein …

Bristol-Myers Squibb and Pfizer’s oral blood thinner Eliquis is as efficient as standard of care and causes less bleeding in …

In a move which will cheer Bristol-Myers Squibb and Pfizer, NICE has recommended oral blood-thinner Eliquis for use on the …

Eliquis has been made available in the UK today to prevent stroke and systemic embolism in patients with nonvalvular atrial …

Bristol-Myers Squibb and Pfizer’s oral blood-thinner Eliquis has been approved in Europe to prevent stroke in patients with nonvalvular atrial …

US regulators have given the go-ahead to expand the indications for which Janssen Pharmaceuticals and Bayer HealthCare’s oral blood thinner …

Bristol-Myers Squibb and Pfizer have received a boost with the CHMP’s recommendation that their co-marketed oral anticoagulant Eliquis should gain …

Xarelto is to be given a FDA fast-track review for a range of anti-blood clotting uses. Xarelto (rivaroxaban) gained its …